Galderma Group AG (CH:GALD)
:GALD
Top Page
Galderma Group AG
(GALD)
Select Model
Select Model
Rating:63Neutral
Price Target:
CHF153.00
▲(2.20% Upside)
Action:DowngradedDate:03/15/26
The score is driven primarily by improving financial performance, including a profitability turnaround, stronger 2025 cash generation, and materially reduced leverage. Offsetting this, technical signals show weakened near-term momentum, and valuation is stretched due to a high P/E despite a supportive dividend yield.
Positive Factors
Profitability turnaround & margins
Galderma has transitioned from multi-year losses to sustained profitability in 2024–2025, supported by very high gross margins (~67–70%) and rising operating leverage (EBIT margin ~16.4% in 2025). This durable earnings base improves capacity to reinvest, fund R&D, and withstand sector cyclicality.
Negative Factors
Sizable absolute debt
Despite improved ratios, an outstanding debt stock of roughly $2.75B represents a lasting fixed-cost and refinancing exposure. In a weaker growth or higher-rate environment, servicing or rolling this debt could constrain discretionary spending, dividend policy, or M&A flexibility over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Profitability turnaround & margins
Galderma has transitioned from multi-year losses to sustained profitability in 2024–2025, supported by very high gross margins (~67–70%) and rising operating leverage (EBIT margin ~16.4% in 2025). This durable earnings base improves capacity to reinvest, fund R&D, and withstand sector cyclicality.
Read all positive factors
Galderma Group AG (GALD) vs. iShares MSCI Switzerland ETF (EWL)
Market Cap
CHF35.15B
Dividend Yield0.09%
Average Volume (3M)337.59K
Price to Earnings (P/E)28.6
Beta (1Y)0.73
Revenue Growth6.22%
EPS GrowthN/A
CountryCH
Employees6,545
SectorHealthcare
Sector Strength45
IndustryHousehold & Personal Products
Share Statistics
EPS (TTM)1.60
Shares Outstanding237,897,630
10 Day Avg. Volume210,266
30 Day Avg. Volume337,589
Financial Highlights & Ratios
PEG Ratio0.61
Price to Book (P/B)4.71
Price to Sales (P/S)8.88
P/FCF Ratio37.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF191.33Price Target Upside27.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)4.59
Revenue Forecast (FY)CHF6.26B
Galderma Group AG Business Overview & Revenue Model
Company Description
Galderma Group AG is engaged in cosmetic industry. Its segment includes Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology....
How the Company Makes Money
Galderma makes money primarily by selling dermatology and aesthetics products through a mix of prescription and non-prescription channels. Revenue is generated from: (1) Injectable aesthetics sold to clinics and healthcare professionals (e.g., neu...
Galderma Group AG Financial Statement Overview
Summary
Income Statement
76
Positive
Balance Sheet
73
Positive
Cash Flow
70
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 4.32B | 4.44B | 3.67B | 3.59B | 3.12B |
| Gross Profit | 2.90B | 3.08B | 2.56B | 2.45B | 2.18B |
| EBITDA | 970.01M | 959.00M | 690.44M | 592.24M | 476.06M |
| Net Income | 509.09M | 231.00M | -48.11M | -94.07M | -141.07M |
Balance Sheet | |||||
| Total Assets | 13.39B | 12.62B | 10.49B | 11.49B | 11.45B |
| Cash, Cash Equivalents and Short-Term Investments | 780.00M | 457.00M | 309.35M | 216.59M | 261.68M |
| Total Debt | 2.75B | 2.76B | 4.13B | 5.23B | 5.18B |
| Total Liabilities | 5.24B | 4.83B | 5.97B | 7.35B | 7.31B |
| Stockholders Equity | 8.15B | 7.79B | 4.52B | 4.13B | 4.14B |
Cash Flow | |||||
| Free Cash Flow | 1.03B | 213.00M | 37.09M | -46.03M | 61.90M |
| Operating Cash Flow | 1.19B | 429.77M | 139.11M | 106.30M | 178.92M |
| Investing Cash Flow | -154.00M | -287.10M | -156.10M | -70.48M | -487.76M |
| Financing Cash Flow | -728.00M | -51.08M | 127.34M | -68.86M | 290.01M |
Galderma Group AG Technical Analysis
Positive
149.70
Price Trends
148.56
Positive
153.18
Negative
142.97
Positive
Market Momentum
-0.52
Negative
53.30
Neutral
88.74
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:GALD, the sentiment is Positive. The current price of 149.7 is above the 20-day moving average (MA) of 147.84, above the 50-day MA of 148.56, and above the 200-day MA of 142.97, indicating a bullish trend. The MACD of -0.52 indicates Negative momentum. The RSI at 53.30 is Neutral, neither overbought nor oversold. The STOCH value of 88.74 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:GALD.
Galderma Group AG Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | CHF218.74B | 18.30 | ― | 3.18% | 7.62% | -18.33% | |
72 Outperform | CHF29.68B | 38.35 | 4.44% | 0.44% | 0.39% | -12.46% | |
66 Neutral | CHF12.96B | 41.72 | ― | 1.02% | 4.49% | 45.08% | |
66 Neutral | CHF26.60B | 32.85 | 2.64% | 1.02% | ― | ― | |
63 Neutral | CHF35.15B | 28.64 | ― | 0.09% | 6.22% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
CH:GALD
Galderma Group AG
149.70
54.43
57.13%
CH:NOVN
Novartis AG
119.82
24.31
25.45%
CH:STMN
Straumann Holding AG
82.00
-23.64
-22.38%
CH:ALC
Alcon
59.40
-22.63
-27.59%
CH:SDZ
Sandoz Group Ltd
60.46
24.71
69.12%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.